201 related articles for article (PubMed ID: 15943026)
1. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
Clavio M; Balleari E; Garrone A; Ballerini F; Varaldo R; Michelis GL; Balocco M; Abdall N; Colombo N; Grasso R; Gobbi M
J Exp Clin Cancer Res; 2005 Mar; 24(1):5-16. PubMed ID: 15943026
[TBL] [Abstract][Full Text] [Related]
2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
Marsh JC; Ganser A; Stadler M
Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
6. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
Greenberg PL; Negrin R; Nagler A
Cancer Surv; 1990; 9(1):199-212. PubMed ID: 2276114
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic growth factors in myelodysplastic syndromes.
Blinder VS; Roboz GJ
Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
10. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
Cazzola M
Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle modulation by hematopoietic growth factors in myelodysplastic syndromes: analysis by three-color flow cytometry.
Ogata K; An E; Kamikubo K; Tamura H; Yokose N; Dan K; Nomura T
Exp Hematol; 1997 Jan; 25(1):8-18. PubMed ID: 8989901
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
13. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Cazzola M
Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
[TBL] [Abstract][Full Text] [Related]
14. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
15. [In vitro effects of hematopoietic growth factors on CD34+ cell from patients with myelodysplastic syndromes].
Yang X; Gu X; Pei X; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 1997 Jul; 18(7):354-7. PubMed ID: 15624331
[TBL] [Abstract][Full Text] [Related]
16. Treatment with growth factors in myelodysplastic syndromes.
Geissler RG; Schulte P; Ganser A
Pathol Biol (Paris); 1997 Oct; 45(8):656-67. PubMed ID: 9569932
[TBL] [Abstract][Full Text] [Related]
17. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
[TBL] [Abstract][Full Text] [Related]
18. Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia.
Wang S; Degar BA; Zieske A; Shafi NQ; Rose MG
Am J Hematol; 2004 Dec; 77(4):391-6. PubMed ID: 15551287
[TBL] [Abstract][Full Text] [Related]
19. [Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study].
Rodríguez JN; Diéguez JC; Muñiz R; Martino ML; Fernández-Jurado A; Amian A; Cañavate M; Prados D
Sangre (Barc); 1994 Dec; 39(6):435-9. PubMed ID: 7855695
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
